Interim Report 1 January - 31 March 2023
• 53% increase in gross order intake and 56% increase in net sales compared to the corresponding quarter of the previous year• Continued growth in user base globally and continued increase in clinical acceptance• Distribution network established in the US ”In the first quarter of 2023, we experienced our best quarter to date in all respects, with higher sales (+56%), greater gross order intake (+53%) and more customers (+20%). On a rolling 12 months basis, the user base, i.e. the number of orthopaedic surgeons who use Episealer®, increased by 46% (105), and user base growth is of